Compare FCCO & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCCO | ENTA |
|---|---|---|
| Founded | 1994 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.5M | 377.5M |
| IPO Year | 2012 | 2012 |
| Metric | FCCO | ENTA |
|---|---|---|
| Price | $33.76 | $12.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 39.2K | ★ 231.6K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 36.46 | 29.93 |
| EPS | ★ 1.39 | N/A |
| Revenue | $922,000.00 | ★ $102,814,000.00 |
| Revenue This Year | $30.67 | $7.76 |
| Revenue Next Year | $5.87 | N/A |
| P/E Ratio | $24.32 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $25.92 | $7.05 |
| 52 Week High | $35.74 | $17.15 |
| Indicator | FCCO | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 45.20 |
| Support Level | $32.44 | $12.19 |
| Resistance Level | $35.45 | $14.03 |
| Average True Range (ATR) | 0.79 | 0.54 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 69.66 | 32.86 |
First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are: Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.